Expanding the use of arsenic trioxide: leukemias and beyond.
about
Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2Carcinogenic effects of "whole-life" exposure to inorganic arsenic in CD1 miceAlterations in glutathione levels and apoptotic regulators are associated with acquisition of arsenic trioxide resistance in multiple myelomaEffect of arsenic trioxide on rat hepatocellular carcinoma and its renal cytotoxitymiRNA-21 regulates arsenic-induced anti-leukemia activity in myelogenous cell lines.Arsenic trioxide-dependent activation of thousand-and-one amino acid kinase 2 and transforming growth factor-beta-activated kinase 1.A novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer.Galectin-3 as a marker and potential therapeutic target in breast cancerCoencapsulation of arsenic- and platinum-based drugs for targeted cancer treatmentAdvances in haematological pharmacotherapy in 21st century.All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemiaFolate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxideArsenic trioxide: an anti cancer missile with multiple warheads.Berberine enhances inhibition of glioma tumor cell migration and invasiveness mediated by arsenic trioxide.Inhibition of hepatitis C virus replication by arsenic trioxide.Caveolin-1 contributes to realgar nanoparticle therapy in human chronic myelogenous leukemia K562 cellsSystematic dissection of dysregulated transcription factor-miRNA feed-forward loops across tumor types.Biography of Zhu Chen.Anti-miR-21 oligonucleotide sensitizes leukemic K562 cells to arsenic trioxide by inducing apoptosis.A facile route to core-shell nanoparticulate formation of arsenic trioxide for effective solid tumor treatment.EZH2 mediates ATO-induced apoptosis in acute myeloid leukemia cell lines through the Wnt signaling pathway.VEGF depletion enhances bcr-abl-specific sensitivity of arsenic trioxide in chronic myelogenous leukemia.Arsenic trioxide induces G2/M arrest in hepatocellular carcinoma cells by increasing the tumor suppressor PTEN expression.Activation of the mitogen- and stress-activated kinase 1 by arsenic trioxide.The cell cycle related apoptotic susceptibility to arsenic trioxide is associated with the level of reactive oxygen species.hsa-miR-203 enhances the sensitivity of leukemia cells to arsenic trioxide.Chronic arsenic intoxication diagnostic score (CAsIDS).Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide.Regulatory effects of mammalian target of rapamycin-mediated signals in the generation of arsenic trioxide responses.Downregulation of ROS1 enhances the therapeutic efficacy of arsenic trioxide in acute myeloid leukemia cell lines.
P2860
Q24317497-8C4C8A64-F372-4A2E-8881-7DB82469D6EBQ24707869-BC9BF43F-5686-4A29-B795-B55118C20677Q28484542-14E7BA6F-30E0-4C42-95D8-F2389B8C0C02Q30921046-00A0EB3A-1E59-42FE-BA15-1F4442EAA44AQ33530333-1E2B5BDA-513B-487D-B964-73ACBFF43DCAQ33862077-4ACA319C-9620-47D0-9884-F630BB248F41Q34145056-AE6805D8-FD3F-4807-B8CB-16943548C2FEQ34257030-3E5FA70D-D339-47C2-8247-34FF8104559EQ34298657-4E14E2C9-D9E5-47D5-B7E5-B7FA097754ABQ34406838-534B965F-BFF8-496C-93B5-5C1F05981DBFQ34546653-3F3F55DE-132B-4A1A-BA30-D490C21C21CAQ34609485-DB7C3CA2-D9AF-4102-A43B-F83FEE595571Q36194579-99F7B53F-3BDA-4DB7-9F60-31A316C9DF4BQ36509566-1A083290-B0A2-4285-B493-3D20E2B3A9A6Q36670022-F3F4ADC1-6309-4AB6-9A41-649012D92880Q37409768-A2C2C840-A9DD-45E6-98D3-7ED22C10DAF9Q37480571-66A55618-7F1C-4300-9910-EDC265A8CAA4Q37712840-2F7E80B2-405D-4578-A02D-F51B4262B73CQ38346521-FA1E349C-6FBA-4F56-B89B-01AD59D069E3Q38796959-E02AE67B-8353-4A43-8B30-7BB907F553E5Q38817863-A93F5ADA-AEC1-4FFD-A452-B07DD57B93D9Q39078119-9BAB8D4F-6A18-4E6F-BC06-5E037A1EB5FFQ39325807-420F35D5-F4BB-427F-8A92-F41254D65C75Q40269885-0A93E80C-998F-4369-8960-DCC396A5B74DQ40574315-04B258C4-A9BC-4401-8C3E-CDB33737C3ABQ41485005-3D403C85-E397-4913-A9EF-746ED58E3F08Q43528346-0370677D-903E-4A35-B5DB-3E30BBDA2941Q44142876-B6C26785-14A7-4D74-8276-BCC9622F70A0Q46874668-C7B4B30B-7DE9-46AB-9156-E104A82DCAADQ54977738-CF6C35C4-B015-4B9B-B159-CA7D9747B723
P2860
Expanding the use of arsenic trioxide: leukemias and beyond.
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Expanding the use of arsenic trioxide: leukemias and beyond.
@ast
Expanding the use of arsenic trioxide: leukemias and beyond.
@en
Expanding the use of arsenic trioxide: leukemias and beyond.
@nl
type
label
Expanding the use of arsenic trioxide: leukemias and beyond.
@ast
Expanding the use of arsenic trioxide: leukemias and beyond.
@en
Expanding the use of arsenic trioxide: leukemias and beyond.
@nl
prefLabel
Expanding the use of arsenic trioxide: leukemias and beyond.
@ast
Expanding the use of arsenic trioxide: leukemias and beyond.
@en
Expanding the use of arsenic trioxide: leukemias and beyond.
@nl
P2093
P356
P1476
Expanding the use of arsenic trioxide: leukemias and beyond.
@en
P2093
Guan-Lin Sun
Guo-Qiang Chen
Jian-Hua Tong
Sai-Juan Chen
Zhen-Yi Wang
Zhi-Xiang Shen
P356
10.1053/SHEM.2002.33611
P433
P577
2002-04-01T00:00:00Z